Following the approval of the first device for transcathether aortic valve replacement therapy (TAVR) earlier this month, the Society of Thoracic Surgeons (STS) and The American College of Cardiology (ACC) have announced the launch of th e TVT Registry, a joint initiative that will monitor the rollout of the new technology.

FORBES: ACC and STS Announce Launch of TAVR Registry

The prestigious American College of Cardiology (ACC) did not accept a controversial study of Merck and Schering-Plough's Vytorin as a highlighted presentation at its annual meeting in March, a key showcase for data on heart drugs, but the group plans to include the presentation at its meeting in some other form.

FORBES: Magazine Article

But then came the artery-imaging study in January and a stinging rebuke from an expert panel last Sunday at the American College of Cardiology's (ACC) meeting.

FORBES: How Low Can Vytorin Go?